Back

HDL-associated phosphatidylserine modulates the myeloid compartment and protects from atherosclerosis

28 August 2026 (12:36 - 12:48)
Organised by: Logo
Congress Presentation Part of: Macrophage biology and inflammation in cardiovascular disease Atherosclerosis, Cerebrovascular Diseases, Aneurysm, Restenosis ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Aurora Bernal

National Centre for Cardiovascular Research (CNIC), Madrid (Spain)

4 More presentations in this session

Presentation thumbnail
Asxl1 clonal hematopoiesis exacerbates abdominal aortic aneurysm through the IRAK2–IRF5 macrophage inflammasome axis
Doctor T. Ueda (Tokyo, JP)
Abstract Slides
Presentation thumbnail
Macrophage mineralocorticoid receptor drives inflammaging in adipose tissue
Mr I. Galuppo (Hannover, DE)
Abstract Slides
Presentation thumbnail
FPR2 agonists exert cardioprotection by resolving inflammatory signalling in macrophages, not cardiomyocytes or cardiac fibroblasts
Ms D. Sosnowski (Montreal, CA)
Abstract Slides
Presentation thumbnail
Epicardial adipose tissue browning attenuates cardiomyocyte ferroptosis in ischemia/reperfusion injury by suppressing ACSL1 cargo loading in M1 macrophage-derived small extracellular vesicles
Doctor Y. Wang (Nanjing, CN)
Abstract Slides

Access the full session

Session thumbnail
Macrophage biology and inflammation in cardiovascular disease
Video

The Event

Event poster

ESC Congress 2026

28 August 2026 12:36 CET
You may be interested in
thumbnail
Congress Presentation
HDL-associated phosphatidylserine normalizes vessel wall metabolism and architecture in atherosclerosis
1 September 2025
thumbnail
Congress Presentation
Macrophage-specific IRF5 deficiency stabilizes atherosclerotic plaques in ApoE-/- mice
31 August 2020
thumbnail
Congress Presentation
Impaired high-density lipoprotein function in patients with heart failure
28 August 2020
thumbnail
Congress Presentation
Effect of 5-lipoxygenase-activating protein inhibiton on coronary atherosclerosis progression in patients with recent acute coronary syndrome: the PASSIVATE randomised clinical trial
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources